Immune modulation in heart failure: Past challenges and future hopes

Current Heart Failure Reports

Volumn 8, Issue 1, 2011, Pages 28-37

  Flores Arredondo, Jose H ^a   García Rivas, Gerardo ^b   Torre Amione, Guillermo ^a,b  

^a HOUSTON METHODIST HOSPITAL   (United States)

^b SCHOOL OF ENGINEERING AND SCIENCES   (Mexico)

Author keywords

Cytokines; Heart failure; Immune modulation; Interleukin 1; Interleukin 6; Intravenous immunoglobulin; Neurohormonal; Therapeutic plasma exchange; Tumor necrosis factor

Indexed keywords

ARACHIDONIC ACID; ETANERCEPT; IMMUNOGLOBULIN; INFLIXIMAB; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 18; INTERLEUKIN 1BETA; INTERLEUKIN 4; INTERLEUKIN 6; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PENTOXIFYLLINE; ROSUVASTATIN; SPHINGOLIPID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; TUMOR NECROSIS FACTOR ALPHA RECEPTOR;

ARTICLE; B LYMPHOCYTE; CARDIAC GRAFT REJECTION; CONGESTIVE CARDIOMYOPATHY; CONGESTIVE HEART FAILURE; CYTOKINE RELEASE; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; IMMUNOMODULATION; LOW DRUG DOSE; MYOCARDITIS; NONHUMAN; PLASMAPHERESIS; SIGNAL TRANSDUCTION; T LYMPHOCYTE; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS; CYTOKINES; HEART FAILURE; HUMANS; IMMUNOLOGIC FACTORS; INFLAMMATION; TREATMENT OUTCOME;

EID: 79551508882     PISSN: 15469530     EISSN: 15469549     Source Type: Journal    
DOI: 10.1007/s11897-010-0044-2     Document Type: Article

References (65)

1. G Torre-Amione S Kapadia J Lee, et al. 1996 Tumor necrosis factor-alpha and tumor necrosis factor receptors in the failing human heart Circulation 93 4 704 11 1:STN:280:DyaK283jtFOqsw%3D%3D 8640999
2. EE Kershaw JS Flier 2004 Adipose tissue as an endocrine organ J Clin Endocrinol Metab 89 6 2548 56 1:CAS:528:DC%2BD2cXmtlGqt7s%3D 15181022 10.1210/jc.2004-0395 (Pubitemid 38766330)
3. SD Prabhu 2004 Cytokine-induced modulation of cardiac function Circ Res 95 12 1140 53 1:CAS:528:DC%2BD2cXhtVensrjL 15591236 10.1161/01.RES.0000150734. 79804.92 (Pubitemid 39648205)
4. G Choudhary SC Dudley Jr 2002 Heart failure, oxidative stress, and ion channel modulation Congest Heart Fail 8 3 148 55 1:CAS:528:DC%2BD38Xlt1CntLw%3D 12045383 10.1111/j.1527-5299.2002.00716.x
5. JL Rothstein H Schreiber 1988 Synergy between tumor necrosis factor and bacterial products causes hemorrhagic necrosis and lethal shock in normal mice Proc Natl Acad Sci U S A 85 2 607 11 1:CAS:528:DyaL1cXhtFSmtbo%3D 3422444 10.1073/pnas.85.2.607
6. B Levine J Kalman L Mayer, et al. 1990 Elevated circulating levels of tumor necrosis factor in severe chronic heart failure N Engl J Med 323 4 236 41 1:STN:280:DyaK3czgvF2isA%3D%3D 2195340 10.1056/NEJM199007263230405
7. B Pajak S Orzechowska B Pijet, et al. 2008 Crossroads of cytokine signaling-the chase to stop muscle cachexia J Physiol Pharmacol 59 Suppl 9 251 64 19261984
8. MS Finkel CV Oddis TD Jacob, et al. 1992 Negative inotropic effects of cytokines on the heart mediated by nitric oxide Science 257 5068 387 9 1:CAS:528:DyaK38XlsV2jsbo%3D 1631560 10.1126/science.1631560
9. G Torre-Amione S Kapadia J Lee, et al. 1995 Expression and functional significance of tumor necrosis factor receptors in human myocardium Circulation 92 6 1487 93 1:CAS:528:DyaK2MXot1yitrc%3D 7664431
10. B Bozkurt SB Kribbs FJ Clubb Jr, et al. 1998 Pathophysiologically relevant concentrations of tumor necrosis factor-alpha promote progressive left ventricular dysfunction and remodeling in rats Circulation 97 14 1382 91 1:CAS:528:DyaK1cXis1KqtL0%3D 9577950
11. DR Wagner A Combes C McTiernan, et al. 1998 Adenosine inhibits lipopolysaccharide-induced cardiac expression of tumor necrosis factor-alpha Circ Res 82 1 47 56 1:CAS:528:DyaK1cXlsVGisw%3D%3D 9440704 (Pubitemid 28074018)
12. EA Palmieri G Benincasa RF Di, et al. 2002 Differential expression of TNF-alpha, IL-6, and IGF-1 by graded mechanical stress in normal rat myocardium Am J Physiol Heart Circ Physiol 282 3 H926 H934 1:CAS:528:DC%2BD38Xit1Ghurw%3D 11834488
13. R Kacimi CS Long JS Karliner 1997 Chronic hypoxia modulates the interleukin-1beta-stimulated inducible nitric oxide synthase pathway in cardiac myocytes Circulation 96 6 1937 43 1:CAS:528:DyaK2sXmsVCis7w%3D 9323084
14. R Ferrari T Bachetti R Confortini, et al. 1995 Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure Circulation 92 6 1479 86 1:CAS:528:DyaK2MXot1yitrY%3D 7664430
15. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators. N Engl J Med. 1991;325(5):293-302.
16. P Seckinger S Isaaz JM Dayer 1988 A human inhibitor of tumor necrosis factor alpha J Exp Med. 167 4 1511 6 1:CAS:528:DyaL1cXitVejsrg%3D 2833558 10.1084/jem.167.4.1511
17. H Engelmann D Aderka M Rubinstein, et al. 1989 A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity J Biol Chem 264 20 11974 80 1:CAS:528:DyaL1MXkslKhtL0%3D 2545693
18. D Hasper M Hummel FX Kleber, et al. 1998 Systemic inflammation in patients with heart failure Eur Heart J 19 5 761 5 1:STN:280: DyaK1czot1Ogug%3D%3D 9717010 10.1053/euhj.1997.0858 (Pubitemid 28227160)
19. BC Henderson SC Tyagi 2006 Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure J Mol Cell Cardiol 41 6 959 62 1:CAS:528:DC%2BD2sXisFaqsw%3D%3D 17046785 10.1016/j.yjmcc.2006.09.001 (Pubitemid 44791336)
20. DG Santos MF Resende JG Mill, et al. 2010 Nuclear Factor (NF) kappaB polymorphism is associated with heart function in patients with heart failure BMC Med Genet 11 89 20534156 10.1186/1471-2350-11-89
21. • Hamid T, Guo SZ, Kingery JR, et al. Cardiomyocyte NF-{kappa}B p65 promotes adverse remodelling, apoptosis, and endoplasmic reticulum stress in heart failure. Cardiovasc Res. 2010 September 16. The implication of NF-κB in various pathways of inflammation and its mysterious role in HF have led to studies to better understand this transcription factor, this article describes its possible role in cardiac remodeling via proinflammatory, profibrotic, and proapoptotic events.
22. A Kalogeropoulos V Georgiopoulou BM Psaty, et al. 2010 Inflammatory markers and incident heart failure risk in older adults: the Health ABC (Health, Aging, and Body Composition) study J Am Coll Cardiol 55 19 2129 37 1:CAS:528:DC%2BC3cXnvVahtL4%3D 20447537 10.1016/j.jacc.2009.12.045
23. G Plenz H Eschert M Erren, et al. 2002 The interleukin-6/interleukin-6- receptor system is activated in donor hearts J Am Coll Cardiol 39 9 1508 12 1:CAS:528:DC%2BD38XktVKksbc%3D 11985915 10.1016/S0735-1097(02)01791-6 (Pubitemid 34439068)
24. G Plenz ZF Song TD Tjan, et al. 2001 Activation of the cardiac interleukin-6 system in advanced heart failure Eur J Heart Fail 3 4 415 21 1:CAS:528:DC%2BD3MXntVSgt7o%3D 11511426 10.1016/S1388-9842(01)00137-4 (Pubitemid 32776868)
25. MA Munger B Johnson IJ Amber, et al. 1996 Circulating concentrations of proinflammatory cytokines in mild or moderate heart failure secondary to ischemic or idiopathic dilated cardiomyopathy Am J Cardiol. 77 9 723 7 1:STN:280:DyaK283gt1Kkuw%3D%3D 8651123 10.1016/S0002-9149(97)89206-5 (Pubitemid 26116687)
26. J Lommi K Pulkki P Koskinen, et al. 1997 Haemodynamic, neuroendocrine and metabolic correlates of circulating cytokine concentrations in congestive heart failure Eur Heart J 18 10 1620 5 1:STN:280:DyaK1c%2Fgs1yhsA%3D%3D 9347273
27. R Kell A Haunstetter TJ Dengler, et al. 2002 Do cytokines enable risk stratification to be improved in NYHA functional class III patients? Comparison with other potential predictors of prognosis Eur Heart J. 23 1 70 8 1:STN:280:DC%2BD3MjgtV2nsA%3D%3D 11741364 10.1053/euhj.2001.2780 (Pubitemid 35215121)
28. CM Thaik A Calderone N Takahashi WS Colucci 1995 Interleukin-1 beta modulates the growth and phenotype of neonatal rat cardiac myocytes J Clin Invest 96 2 1093 9 1:CAS:528:DyaK2MXnsVans7k%3D 7635944 10.1172/JCI118095
29. LB Daniels P Clopton N Iqbal, et al. 2010 Association of ST2 levels with cardiac structure and function and mortality in outpatients Am Heart J 160 4 721 8 1:CAS:528:DC%2BC3cXht1Kqtr%2FI 20934567 10.1016/j.ahj.2010.06.033
30. SD Katz R Rao JW Berman, et al. 1994 Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation Circulation 90 1 12 6 1:CAS:528:DyaK2cXmtVaitb4%3D 8025986
31. DA Pascual-Figal J Ordonez-Llanos PL Tornel, et al. 2009 Soluble ST2 for predicting sudden cardiac death in patients with chronic heart failure and left ventricular systolic dysfunction J Am Coll Cardiol 54 23 2174 9 1:CAS:528:DC%2BC3cXkvFOhsQ%3D%3D 19942089 10.1016/j.jacc.2009.07.041
32. B Stein P Frank W Schmitz, et al. 1996 Endotoxin and cytokines induce direct cardiodepressive effects in mammalian cardiomyocytes via induction of nitric oxide synthase J Mol Cell Cardiol. 28 8 1631 9 1:CAS:528: DyaK28XlsF2jt7s%3D 8877773 10.1006/jmcc.1996.0153 (Pubitemid 26300563)
33. MW Cunningham 2006 T regulatory cells: sentinels against autoimmune heart disease Circ Res. 99 10 1024 6 1:CAS:528:DC%2BD28Xht1yitLvI 17095729 10.1161/01.RES.0000250832.30969.6a (Pubitemid 44729924)
34. LA Blauwet LT Cooper 2010 Myocarditis Prog Cardiovasc Dis. 52 4 274 88 20109598 10.1016/j.pcad.2009.11.006
35. NR Rose 2009 Myocarditis: infection versus autoimmunity J Clin Immunol. 29 6 730 7 1:CAS:528:DC%2BD1MXhsFWitLvJ 19826933 10.1007/s10875-009-9339-z
36. M Mengel B Sis D Kim, et al. 2010 The molecular phenotype of heart transplant biopsies: relationship to histopathological and clinical variables Am J Transplant. 10 9 2105 15 1:STN:280:DC%2BC3cfmt1KqsA%3D%3D 20883545 10.1111/j.1600-6143.2010.03182.x
37. M Moulik JP Breinholt WJ Dreyer, et al. 2010 Viral endomyocardial infection is an independent predictor and potentially treatable risk factor for graft loss and coronary vasculopathy in pediatric cardiac transplant recipients J Am Coll Cardiol. 56 7 582 92 20688214 10.1016/j.jacc.2010.02.060
38. KS Cunningham JP Veinot J Butany 2006 An approach to endomyocardial biopsy interpretation J Clin Pathol. 59 2 121 9 1:STN:280: DC%2BD28%2FlvVOltg%3D%3D 16443725 10.1136/jcp.2005.026443 (Pubitemid 43235574)
39. Z Kaya HA Katus NR Rose 2010 Cardiac troponins and autoimmunity: their role in the pathogenesis of myocarditis and of heart failure Clin Immunol. 134 1 80 8 1:CAS:528:DC%2BD1MXhsFGgtLvM 19446498 10.1016/j.clim.2009.04.008
40. AL Caforio NJ Mahon F Tona WJ McKenna 2002 Circulating cardiac autoantibodies in dilated cardiomyopathy and myocarditis: pathogenetic and clinical significance Eur J Heart Fail. 4 4 411 7 12167378 10.1016/S1388- 9842(02)00010-7 (Pubitemid 36564958)
41. AL Caforio NJ Mahon WJ McKenna 2001 Cardiac autoantibodies to myosin and other heart-specific autoantigens in myocarditis and dilated cardiomyopathy Autoimmunity 34 3 199 204 1:CAS:528:DC%2BD38XhvFOhsrw%3D 11908778 10.3109/08916930109007385
42. • Bjerre M, Kistorp C, Hansen TK, et al. Complement activation, endothelial dysfunction, insulin resistance and chronic heart failure. Scand Cardiovasc J. 2010 June 7. Diabetes long has been associated with increased risk for cardiovascular disease. The authors hypothesize, based on preliminary evidence, that insulin resistance leads to complement activation and, subsequently, damage of heart tissues.
43. K Kohno Y Takagaki N Aoyama, et al. 2001 A peptide fragment of beta cardiac myosin heavy chain (beta-CMHC) can provoke autoimmune myocarditis as well as the corresponding alpha cardiac myosin heavy chain (alpha-CMHC) fragment Autoimmunity 34 3 177 85 1:CAS:528:DC%2BD38XhvFOhsr4%3D 11908775 10.3109/08916930109007382
44. DJ Marchant BM McManus 2010 Regulating viral myocarditis: allografted regulatory T cells decrease immune infiltration and viral load Circulation 121 24 2609 11 20529996 10.1161/CIRCULATIONAHA.110.960054
45. T Yajima KU Knowlton 2009 Viral myocarditis: from the perspective of the virus Circulation 119 19 2615 24 19451363 10.1161/CIRCULATIONAHA.108.766022
46. K Triantafilou G Orthopoulos E Vakakis, et al. 2005 Human cardiac inflammatory responses triggered by Coxsackie B viruses are mainly Toll-like receptor (TLR) 8-dependent Cell Microbiol. 7 8 1117 26 1:CAS:528: DC%2BD2MXntVSntrk%3D 16008579 10.1111/j.1462-5822.2005.00537.x (Pubitemid 41030937)
47. EM Oestreicher D Martinez-Vasquez JR Stone, et al. 2003 Aldosterone and not plasminogen activator inhibitor-1 is a critical mediator of early angiotensin II/NG-nitro-L-arginine methyl ester-induced myocardial injury Circulation 108 20 2517 23 1:CAS:528:DC%2BD3sXovVeku7k%3D 14581407 10.1161/01.CIR.0000097000.51723.6F (Pubitemid 37444415)
48. DL Mann JJ McMurray M Packer, et al. 2004 Targeted anticytokine therapy in patients with chronic heart failure: results of the randomized Etanercept Worldwide Evaluation (RENEWAL) Circulation 109 13 1594 602 1:CAS:528: DC%2BD2cXisFOqtr4%3D 15023878 10.1161/01.CIR.0000124490.27666.B2 (Pubitemid 38451714)
49. ES Chung M Packer KH Lo, et al. 2003 Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-alpha, in patients with moderate-to-severe heart failure: results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial Circulation 107 25 3133 40 1:CAS:528:DC%2BD3sXkslKgtrs%3D 12796126 10.1161/01.CIR.0000077913.60364.D2 (Pubitemid 36793081)
50. L Gullestad H Aass JG Fjeld, et al. 2001 Immunomodulating therapy with intravenous immunoglobulin in patients with chronic heart failure Circulation 103 2 220 5 1:CAS:528:DC%2BD3MXhtFajtrs%3D 11208680
51. DM McNamara R Holubkov RC Starling, et al. 2001 Controlled trial of intravenous immune globulin in recent-onset dilated cardiomyopathy Circulation 103 18 2254 9 1:CAS:528:DC%2BD3MXkt1Gnt7s%3D 11342473
52. A Staudt A Hummel J Ruppert, et al. 2006 Immunoadsorption in dilated cardiomyopathy: 6-month results from a randomized study Am Heart J 152 4 712 6 16996843 10.1016/j.ahj.2006.06.027 (Pubitemid 44396901)
53. A Staudt Y Staudt M Dorr, et al. 2004 Potential role of humoral immunity in cardiac dysfunction of patients suffering from dilated cardiomyopathy J Am Coll Cardiol 44 4 829 36 15312867 10.1016/j.jacc.2004.04.055 (Pubitemid 39099581)
54. G Torre-Amione F Sestier B Radovancevic J Young 2005 Broad modulation of tissue responses (immune activation) by celacade may favorably influence pathologic processes associated with heart failure progression Am J Cardiol 95 11A 30C 7C 1:CAS:528:DC%2BD2MXlsFSmtbk%3D 15925562 10.1016/j.amjcard.2005.03.010 (Pubitemid 40755516)
55. G Torre-Amione F Sestier B Radovancevic J Young 2004 Effects of a novel immune modulation therapy in patients with advanced chronic heart failure: results of a randomized, controlled, phase II trial J Am Coll Cardiol. 44 6 1181 6 15364317 10.1016/j.jacc.2004.06.047 (Pubitemid 39208871)
56. G Torre-Amione SD Anker RC Bourge, et al. 2008 Results of a non-specific immunomodulation therapy in chronic heart failure (ACCLAIM trial): a placebo-controlled randomised trial Lancet 371 9608 228 36 1:CAS:528: DC%2BD1cXotlOntw%3D%3D 18207018 10.1016/S0140-6736(08)60134-8
57. G Torre-Amione RC Bourge WS Colucci, et al. 2007 A study to assess the effects of a broad-spectrum immune modulatory therapy on mortality and morbidity in patients with chronic heart failure: the ACCLAIM trial rationale and design Can J Cardiol. 23 5 369 76 17440642
58. K Sliwa A Woodiwiss VN Kone, et al. 2004 Therapy of ischemic cardiomyopathy with the immunomodulating agent pentoxifylline: results of a randomized study Circulation 109 6 750 5 1:CAS:528:DC%2BD2cXhtFWltLY%3D 14970111 10.1161/01.CIR.0000112568.48837.60 (Pubitemid 38222895)
59. CK Wallace SJ Stetson SA Kucuker, et al. 2005 Simvastatin decreases myocardial tumor necrosis factor alpha content in heart transplant recipients J Heart Lung Transplant. 24 1 46 51 15653378 10.1016/j.healun.2003.09.037 (Pubitemid 40093991)
60. J Kjekshus E Apetrei V Barrios, et al. 2007 Rosuvastatin in older patients with systolic heart failure N Engl J Med. 357 22 2248 61 1:CAS:528:DC%2BD2sXhsVSlsLvI 17984166 10.1056/NEJMoa0706201 (Pubitemid 350190755)
61. L Tavazzi AP Maggioni R Marchioli, et al. 2008 Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial Lancet 372 9645 1231 9 18757089 10.1016/S0140-6736(08)61240-4
62. JJ McMurray J Kjekshus L Gullestad, et al. 2009 Effects of statin therapy according to plasma high-sensitivity C-reactive protein concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): a retrospective analysis Circulation 120 22 2188 96 1:CAS:528:DC%2BD1MXhsVertrfK 19917888 10.1161/CIRCULATIONAHA.109.849117
63. AP Koo 2000 Therapeutic apheresis in autoimmune and rheumatic diseases J Clin Apher. 15 1-2 18 27 1:STN:280:DC%2BD3c3ivFOgsQ%3D%3D 10767049 10.1002/(SICI)1098-1101(2000)15:1/2<18::AID-JCA3>3.0.CO;2-R
64. ME Brecher 2002 Plasma exchange: why we do what we do J Clin Apher 17 4 207 11 12494415 10.1002/jca.10041 (Pubitemid 36015436)
65. Torre-Amione G, Orrego CM, Khalil N, et al. Therapeutic plasma exchange a potential strategy for patients with advanced heart failure. J Clin Apher 2010 September 24.